rare disease portfolio

Game-Changing Acquisition: Essential Pharma Takes Over Renaissance Pharma to Revolutionize Pediatric Neuroblastoma Treatment

📢 Essential Pharma acquires Renaissance Pharma Ltd to commercialize Phase II program Hu14.18K322A, showing promising results in pediatric high-risk neuroblastoma.